Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.
Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Central serous chorioretinopathy group | Experimental | Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide. |
|
| Irvine-Gass Syndrome group | Experimental | Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Triamcinolone Acetonide | Drug | Suprachoroidal injection of triamcinolone acetonide |
|
| Measure | Description | Time Frame |
|---|---|---|
| Central macular thickness | Changes in central macular thickness (CMT) measured in millimeters (mm) by optical coherence tomography (OCT) | Baseline and 12 months after injection. |
| Measure | Description | Time Frame |
|---|---|---|
| Best corrected visual acuity | Changes in best corrected visual acuity (BCVA) measured in logarithm of minimal angle of resolution (LogMAR) by chart projector. | Baseline and 12 months after injection. |
| Measure | Description | Time Frame |
|---|---|---|
| Intraocular pressure | Changes in intraocular pressure (IOP) measured in millimeter mercury (mmHg) by applanation tonometry. | Baseline and 12 months after injection. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed Abdelshafy, MD | Contact | 01222328766 | ahmad4lg@gmail.com | |
| Marwa Abdelshafy, MD | Contact | 01222328766 | ahmad4lg@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ahmed A Abdelshafy, MD | Benha University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ahmed Abdelshafy | Recruiting | Banhā | QA | 13511 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D056833 | Central Serous Chorioretinopathy |
| D008269 | Macular Edema |
| D015868 | Pars Planitis |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |
Not provided
Not provided
| ID | Term |
|---|---|
| D014222 | Triamcinolone Acetonide |
| ID | Term |
|---|---|
| D014221 | Triamcinolone |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D002833 |
| Choroiditis |
| D015862 | Choroid Diseases |
| D014603 | Uveal Diseases |
| D015866 | Uveitis, Posterior |
| D015864 | Panuveitis |
| D014605 | Uveitis |
| D015867 | Uveitis, Intermediate |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |